Status:
TERMINATED
Cholecystokinin for Reducing Binge Eating in People With Bulimia Nervosa
Lead Sponsor:
New York State Psychiatric Institute
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Bulimia Nervosa
Eating Disorders
Eligibility:
FEMALE
18-55 years
Phase:
NA
Brief Summary
This study will determine the effectiveness of administrating a dose of cholecystokinin during a binge eating episode in reducing this eating behavior in people with bulimia nervosa.
Detailed Description
Bulimia Nervosa (BN) is a serious eating disorder that is characterized by frequent uncontrolled eating binges. These binges are often followed by compensatory behavior, including the following: self-...
Eligibility Criteria
Inclusion
- Inclusion Criteria for Patients with BN:
- Meets DSM-IV criteria for BN
- BN duration of more than 1 year
- Self-induces vomiting
- Weighs between 80 and 120% of ideal body weight
- Exclusion Criteria for Patients with BN:
- Significant medical illness
- Current or lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder, as defined by DSM-IV-TR criteria
- Current DSM-IV-TR diagnosis of organic mental disorder, factitious disorder, or malingering
- History of a personality disorder (e.g., schizotypal, borderline, or antisocial) that might interfere with the study procedures
- At risk for suicide, as defined by the expression of an imminent plan or attempt within the 6 months prior to study entry
- Currently taking psychotropic medications or medications that affect gastrointestinal function
- Moderate to severe depression, as defined by a score of greater than 28 on the Hamilton Depression Rating Scale
- Drug or alcohol abuse within the 3 months prior to study entry
- Pregnant, planning to become pregnant, or lactating
- Body mass index (BMI) of less than 18 (underweight)
- Inclusion Criteria for Normal Weight Controls:
- No current or past psychiatric history
- No history of binge eating or vomiting
- 80-120% of ideal body weight
- Exclusion Criteria for Normal Weight Controls:
- Significant medical illness
- Current psychotropic medications and current medications that affect GI function
- Drug or alcohol abuse in last 3 months
- Pregnancy, planning to become pregnant or laction
Exclusion
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00308776
Start Date
October 1 2003
End Date
October 1 2008
Last Update
May 28 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York State Psychiatric Institute
New York, New York, United States, 10032